$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the national unified selling price of Jisandai/Bingtongsha? How much does the patient need to pay out of pocket after being reimbursed by medical insurance?
2026-02-01 22:25:32
Check Details
Seven major side effects of sunitinib: common adverse reactions and preventive measures
2026-02-01 22:25:32
Check Details
What are the side effects of tazetostat? How do patients respond scientifically?
2026-02-01 22:25:32
Check Details
Comparison of targeted therapeutic mechanisms and indications between dabrafenib/dabrafenib and trametinib
2026-02-01 22:25:32
Check Details
How much does Osimertinib/Tagressa cost after medical insurance reimburses it? Interpretation of the latest prices and policies in 2025
2026-02-01 22:25:32
Check Details
Detailed instructions for Eltrombopag/Eltrombopag Tablets and medication guide are here!
2026-02-01 22:25:32
Check Details
How long does it take for Roprostim/Romigrastim to take effect after injection? Onset of effect and clinical feedback
2026-02-01 22:25:32
Check Details
Axitinib/Axitinib Tablets Usage and Dosage Guidelines
2026-02-01 22:25:32
Check Details
Comparing the prices of dabrafenib and trametinib in China, which one is more affordable?
2026-02-01 22:25:32
Check Details
Imatinib/Gleevec: chemotherapy drug or targeted therapy?
2026-02-01 22:25:32
Check Details
A complete introduction to ruxolitinib phosphate/ruxolitinib cream: functions and usage in one place!
2026-02-01 22:25:32
Check Details
The efficacy and role of Jisandai/Bingtonsha: Why is it the drug of choice for the treatment of hepatitis C?
2026-02-01 22:25:32
Check Details
1
2
...
1422
1423
1424
1425
1426
1427
1428
...
10239
10240
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Anagrelide Cautions and Contraindications: Allergy, Hepatic, Cardiac and Bleeding Risks
4
FDA Accelerated Approval of Voceryq: First Plasmid DNA Immunotherapy for Adult Recurrent Respiratory Papillomatosis
5
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
6
Revumenib: Key Considerations Before and During Treatment
7
Pacritinib in Myelofibrosis: Evidence on Spleen Volume Reduction and Symptom Control
8
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
9
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
10
Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use
11
Dasatinib: A BCR-ABL Targeted TKI, Not Conventional Chemo
12
Obeticholic Acid (OCA): FXR Therapy in PBC and Liver Safety Limits